

**Haleh BAGHERI** - Publications 2015-2017

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

*Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales*  
*Mise à jour janvier 2018*

---

## 2017

1. Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, [Bagheri H](#), Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, Lapeyre-Mestre M, Newton PN, Roussin A. [Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People's Democratic Republic](#). Drug Saf. 2017 Sep;40(9):809-821. doi: 10.1007/s40264-017-0544-z.
2. Couture G, Delzor F, [Bagheri H](#), Micallef J, Ruysen-Witrand A, Laroche M. [First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy](#). Joint Bone Spine. 2017 Mar;84(2):213-215. doi: 10.1016/j.jbspin.2016.11.004.
3. Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, [Bagheri H](#), Montastruc F, Montastruc JL. [Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase® , the WHO pharmacovigilance database](#). Fundam Clin Pharmacol. 2017 Jun;31(3):359-366. doi: 10.1111/fcp.12264.
4. Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL, [Bagheri H](#). [Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France](#). Eur J Clin Pharmacol. 2017 Apr;73(4):471-477. doi: 10.1007/s00228-016-2185-z.
5. Montastruc F, [Bagheri H](#), Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting](#). Drug Saf. 2017 Dec 21. doi: 10.1007/s40264-017-0630-2. [Epub ahead of print]
6. Nguyen KD, Nguyen PT, Nguyen HA, Roussin A, Montastruc JL, [Bagheri H](#), Olsson S. [Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country](#). Drug Saf. 2017 Oct 3. doi: 10.1007/s40264-017-0598-y. [Epub ahead of print]
7. Nguyen KD, Nguyen PT, Nguyen HA, Roussin A, Montastruc JL, [Bagheri H](#), Olsson S. [Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country](#). Drug Saf. 2017 Oct 3. doi: 10.1007/s40264-017-0598-y. [Epub ahead of print]
8. Severino-Freire M, Lamant L, [Bagheri H](#), Mazereeuw-Hautier J, Paul C. [\[Drug eruption with clomifene citrate in a bodybuilder\]](#). Ann Dermatol Venereol. 2017 Jun 20. pii: S0151-9638(17)30229-6. doi:

## 2016

1. [Bagheri H](#), Lacroix I, Guitton E, Damase-Michel C, Montastruc JL. [Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?](#) Therapie. 2016 Apr;71(2):235-9. doi: 10.1016/j.therap.2015.09.002.
2. [Bagheri H](#), Laroche ML, Montastruc JL. [Pharmacovigilance: The new challenges](#). Therapie. 2016 Apr;71(2):121-2. doi: 10.1016/j.therap.2016.02.019.

3. Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, [Bagheri H](#), Huguet F, Despas F, Pathak A, Montastruc JL. [Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy](#). Target Oncol. 2016 Aug;11(4):549-52. doi: 10.1007/s11523-016-0417-x.
4. Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, [Bagheri H](#). [Risk of hormone therapy in transgender people: Literature review and data from the French Database of Pharmacovigilance](#). Ann Endocrinol (Paris). 2016 Feb;77(1):14-21. doi: 10.1016/j.ando.2015.12.001.
5. Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, [Bagheri H](#), Montastruc F. [Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study](#). Pharmacol Res. 2016 Jun 2. pii: S1043-6618(16)30493-5. doi: 10.1016/j.phrs.2016.05.024.
6. De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, [Bagheri H](#), Rascol O, Pariente A, Bégaud B, Montastruc F. [Atropinic \(Anticholinergic\) Burden in Parkinson's Disease](#). Mov Disord. 2016 May;31(5):632-6. doi: 10.1002/mds.26595.
7. Durrieu G, Jacquot J, Baudrin D, Mège M, Rousseau V, [Bagheri H](#), Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. [\[Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits\]](#). Therapie. 2016 Oct 27. pii: S0040-5957(16)31206-9. doi: 10.1016/j.therap.2016.09.004.
8. Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, [Bagheri H](#). [Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years](#). Eur J Clin Pharmacol. 2016 May;72(5):631-9. doi: 10.1007/s00228-016-2022-4.
9. Montastruc JL, Chebane L, [Bagheri H](#). [Comment on: "Drug-Induced Hyperglycaemia and Diabetes"](#). Drug Saf. 2016 May;39(5):465-6. doi: 10.1007/s40264-016-0397-x.
10. Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugno G, Montastruc JL, [Bagheri H](#). [Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database](#). Fundam Clin Pharmacol. 2016 Apr;30(2):162-71. doi: 10.1111/fcp.12171.
11. Thorel J, McCambridge C, Piau A, Secher M, Magre É, Montastruc JL, [Bagheri H](#). [\[Proton pump inhibitors: Real indication or trivialized prescription?\]](#) Therapie. 2016 Dec;71(6):589-593. doi: 10.1016/j.therap.2016.05.008.

## 2015

1. Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, Durrieu G, Chebane L, Giroud JP, [Bagheri H](#), Montastruc JL. [Adverse drug reactions to self-medication: a study in a pharmacovigilance database](#). Fundam Clin Pharmacol. 2015 Oct;29(5):517-20. doi: 10.1111/fcp.12140.
2. Chebane L, [Bagheri H](#), Hillaire-Buys D, Géniaux H, Yahoui N, Laroche ML, Cottin J, Spreux A, Mosquet B, Pecriaux C, Bellet F, Lambert A, Montastruc JL. [\[Drug-induced pancreatitis. A review of French spontaneous reports\]](#). Rev Med Interne. 2015 Sep;36(9):573-8. doi: 10.1016/j.revmed.2015.04.012.
3. Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Pérault-Pochat MC, [Bagheri H](#), Montastruc JL. [Drugs and Sleep Apneas? A review of the French Pharmacovigilance database](#). Therapie. 2015 Jul-Aug;70(4):347-50. doi: 10.2515/therapie/2014218.
4. Montastruc F, Palmaro A, [Bagheri H](#), Schmitt L, Montastruc JL, Lapeyre-Mestre M. [Role of serotonin 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-](#)

- [pharmacodynamic study in Vigibase](#). Eur Neuropsychopharmacol. 2015 Oct;25(10):1556-65. doi: 10.1016/j.euroneuro.2015.07.010.
5. Montastruc F, Rouanet S, Gardette V, Rousseau V, [Bagheri H](#), Montastruc JL. [[Hospital readmission induced by adverse drug reaction: a pilot study in a post-emergency unit of a French university hospital](#)]. Rev Med Interne. 2015 Jul;36(7):450-6. doi: 10.1016/j.revmed.2014.11.016.
  6. Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, Montastruc F, [Bagheri H](#). [Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists \(VKA\) and direct oral anticoagulants \(DOA\)](#). Eur J Clin Pharmacol. 2015 Oct;71(10):1283-4. doi: 10.1007/s00228-015-1905-0.
  7. Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, [Bagheri H](#). [[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation](#)]. Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032.
  8. Thorel J, Civade E, Quintyn JC, Cestac P, Montastruc JL, [Bagheri H](#). [Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?](#) J Clin Pharm Ther. 2015 Aug;40(4):477-9. doi: 10.1111/jcpt.12278.